Athira Pharma, Inc. has rebranded as LeonaBio, Inc. with a new ticker symbol, "LONA," following a transformative acquisition.
LeonaBio's name change aligns with its commitment to advancing innovative therapies, including a Phase 3 program for metastatic breast cancer treatment.
The company's mission focuses on developing novel therapeutics for diseases with high unmet medical needs.
Name Change
Athira Pharma has officially become LeonaBio, Inc. to reflect its recent acquisition and commitment to innovation.
Ticker Symbol
The company's new ticker symbol on NASDAQ will be "LONA" starting January 12, 2026.
Clinical Assets
LeonaBio is dedicated to developing lasofoxifene and ATH-1105 as potential therapeutic options for metastatic breast cancer and ALS.
- The acquisition of rights to lasofoxifene for metastatic breast cancer treatment marks a significant step in LeonaBio's strategic expansion.
- The company's financing of $90 million, with potential additional funding of $146 million, demonstrates strong investor support for its clinical development goals.
LeonaBio's transformation signifies a pivotal moment in its journey towards delivering transformative therapies for patients in need. The new name and focus on late-stage assets highlight its dedication to innovation and patient-centered care.